Hannah Brendan has filed 17 insider transactions across 1 company since February 2024.
Most recent transaction: a grant/award of 365000 shares of Quince Therapeutics, Inc. ($QNCX) on January 23, 2026.
Activity breakdown: 6 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 23, 2026 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CBO, COO & CCO | A | Employee Stock Option (Right to Buy) | 365000 | $0.00 | 365,000.0000 | 55,681,490 | 50.00% | 0.66% |
| Dec. 5, 2025 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CBO, COO & CCO | M | Common Shares | 25280 | $0.94 | 361,827.0000 | 55,681,490 | 7.51% | 0.05% |
| Dec. 5, 2025 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CBO, COO & CCO | M | Common Shares | 2271 | $0.55 | 336,547.0000 | 55,681,490 | 0.68% | 0.00% |
| Dec. 5, 2025 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CBO, COO & CCO | M | Employee Stock Option (Right to Buy) | 25280 | $0.00 | 199,720.0000 | 55,681,490 | 11.24% | 0.05% |
| Dec. 5, 2025 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CBO, COO & CCO | M | Employee Stock Option (Right to Buy) | 2271 | $0.00 | 45,168.0000 | 55,681,490 | 4.79% | 0.00% |
| June 18, 2025 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CBO, COO & CCO | A | Common Shares | 37736 | $1.20 | 334,276.0000 | 44,001,643 | 12.73% | 0.09% |
| June 18, 2025 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CBO, COO & CCO | A | Warrants | 37736 | $0.13 | 37,736.0000 | 44,001,643 | 9999.99% | 0.09% |
| Jan. 28, 2025 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CBO, COO and CCO | A | Employee Stock Option (right to buy) | 450000 | $0.00 | 450,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 21, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | P | Common Stock | 23565 | $0.63 | 296,540.0000 | 0 | 8.63% | 0.00% |
| Aug. 21, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | P | Common Stock | 2280 | $0.61 | 267,975.0000 | 0 | 0.86% | 0.00% |
| Aug. 20, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | P | Common Stock | 3424 | $0.60 | 265,695.0000 | 0 | 1.31% | 0.00% |
| Aug. 20, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | P | Common Stock | 2500 | $0.61 | 262,271.0000 | 0 | 0.96% | 0.00% |
| Aug. 19, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | P | Common Stock | 2155 | $0.58 | 259,771.0000 | 0 | 0.84% | 0.00% |
| Aug. 21, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | P | Common Stock | 5000 | $0.62 | 272,975.0000 | 0 | 1.87% | 0.00% |
| June 4, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | M | Employee Stock Option (right to buy) | 56061 | $0.00 | 47,439.0000 | 0 | 54.17% | 0.00% |
| June 4, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | M | Common Stock | 56061 | $0.55 | 257,616.0000 | 0 | 27.81% | 0.00% |
| Feb. 1, 2024 | Quince Therapeutics, Inc. | $QNCX | Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | A | Employee Stock Option (right to buy) | 600000 | $0.00 | 600,000.0000 | 0 | 9999.99% | 0.00% |